BACKGROUND: 17-alpha Hydroxyprogesterone caproate for prevention of recurrent preterm birth is recommended for use in the United States. OBJECTIVE: We sought to assess the clinical effectiveness of 17-alpha hydroxyprogesterone caproate to prevent recurrent preterm birth 35 weeks compared to similar births in our obstetric population prior to the implementation of 17-alpha hydroxyprogesterone caproate. STUDY DESIGN: This was a prospective cohort study of 17-alpha hydroxyprogesterone caproate in our obstetric population. The primary outcome was the recurrence of birth 35 weeks for the entire study cohort compared to a historical referent rate of 16.8% of recurrent preterm birth in our population. There were 3 secondary outcomes. First, did 17-alpha hydroxyprogesterone caproate modify a woman's history of preterm birth when taking into account her prior number and sequence of preterm and term births? Second, was recurrence of preterm birth related to 17-alpha hydroxyprogesterone caproate plasma concentration? Third, was duration of pregnancy modified by 17-alpha hydroxyprogesterone caproate treatment compared to a prior preterm birth? RESULTS: From January 2012 through March 2016, 430 consecutive women with prior births 35 weeks were treated with 17-alpha hydroxyprogesterone caproate. Nearly two thirds of the women (N ¼ 267) began injections 18 weeks and 394 (92%) received a scheduled weekly injection within 10 days of reaching 35 weeks or delivery. The overall rate of recurrent preterm birth was 25% (N ¼ 106) for the entire cohort compared to the 16.8% expected rate (P ¼ 1.0). The 3 secondary outcomes were also negative. First, 17-alpha hydroxyprogesterone caproate did not significantly reduce the rates of recurrence regardless of prior preterm birth number or sequence. Second, plasma concentrations of 17-alpha hydroxyprogesterone caproate were not different (P ¼ .17 at 24 weeks; P ¼ .38 at 32 weeks) between women delivered 35 weeks and those delivered later in pregnancy. Third, the mean (AESD) interval in weeks of recurrent preterm birth before 17-alpha hydroxyprogesterone caproate use was 0.4 AE 5.3 weeks and the interval of recurrent preterm birth after 17-alpha hydroxyprogesterone caproate treatment was 0.1 AE 4.7 weeks (P ¼ .63). A side effect of weekly 17-alpha hydroxyprogesterone caproate injections was an increase in gestational diabetes. Specifically, the rate of gestational diabetes was 13.4% in 17-alpha hydroxyprogesterone caproateetreated women compared to 8% in case-matched controls (P ¼ .001). CONCLUSION: 17-alpha Hydroxyprogesterone caproate was ineffective for prevention of recurrent preterm birth and was associated with an increased rate of gestational diabetes.
Introduction
Prevention of preterm birth is a major focus in obstetrics due to the burden of neonatal morbidity and mortality on mothers, infants, families, and society both medically and financially. Dollar costs due to prematurity in the United States in 2006 were estimated to be >$26 billion. 1 Moreover, the consequences of prematurity include long-term neurological complications due to immaturity related injuries to the brain. 2 Consequently, development of interventions to reduce the rate of preterm birth have been emphasized in the United States for several decades. A recent example is the widespread use of progestogens to prevent preterm birth. [3] [4] [5] [6] [7] [8] [9] 17-alpha Hydroxyprogesterone caproate (17 OHP-C), a synthetic progestogen, is the first and only agent to date approved for marketing by the US Food and Drug Administration (FDA) for prevention of recurrent preterm birth. 10 This approval stems from a trial by Meis and colleagues 3 published in 2003. Following FDA approval, the American Congress of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine (SMFM) endorsed use of 17 OHP-C for prevention of recurrent preterm birth in singleton gestations. 11, 12 Most recently (January 2017), the SMFM Publications Committee recommended 17 OHP-C be used for prevention of recurrent preterm birth and that vaginal progesterone should not be considered a substitute for 17 OHP-C. 13 The SMFM Publications Committee also concluded that despite their recommendations, there continued to be underutilization of 17 OHP-C. 13 It is important to emphasize that the FDA approval of 17 OHP-C was under a regulatory pathway (Subpart H of the FDA Code of Regulations) used when the decision is made on the basis of a surrogate endpointedelivery <37 weeks of gestation in this caseeand was deemed to require further studies. 14 In fact, another placebo-controlled randomized trial of 17 OHP-C is in progress in the United States and elsewhere with the FDA-preferred primary endpoint of delivery <35 weeks' gestation. Details of this ongoing trial titled, "Confirmatory Study of 17P Versus Vehicle for the Related editorial, page 543.
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Prevention of Preterm Birth in Women with a Previous Singleton Spontaneous Preterm Delivery," can be found at: https://clinicaltrials.gov/ct2/show/NCT0 1004029. 14, 15 This study began in October 2009 with an originally predicted date for conclusion of October 2013, which has been moved to 2018. 14, 15 This trial is sponsored by the manufacturer Lumara Health Inc.
We organized a study to introduce 17 OHP-C into our clinical practice. We elected not to attempt a single-center randomized trial due to the high expense of such trials as well as the fact that the prevalence of recurrent preterm birth essentially obviates a single-center trial in a practical time period. Moreover, we wanted to perform a real-world study given the generalizability limitations of traditional randomized trials. 16, 17 We now report our experience with administration of 17 OHP-C to women delivered at our hospital. We were particularly interested in the effectiveness of 17 OHP-C using each womaneand her specific history of preterm birtheas the benchmark to measure response to therapy. Put another way, we introduced a widely used therapy in the United States to prevent recurrent preterm birth and measured whether or not this therapy was beneficial for the women actually treated in our practice.
Materials and Methods

Study design
Parkland Hospital serves the medically indigent women of Dallas County and has developed a neighborhood-based, administratively and medically integrated public health care system for inner-city women. All women delivering at our hospital are routinely assigned to a Parkland Hospital neighborhood clinic for antenatal and postpartum care. Upon enrollment into prenatal care, women with a history of preterm birth are referred to the Preterm Birth Clinic centrally located at Parkland Hospital. This is a specific high-risk prenatal clinic staffed by maternal-fetal medicine faculty and fellows from the University of Texas Southwestern Medical Center. Criteria for referral to this clinic included a singleton pregnancy and prior spontaneous preterm birth or rupture of membranes between 20 0/7 and 35 0/7 weeks' gestation. All women were offered 17 OHP-C therapy commencing Jan. 1, 2012. Prior to this date 17 OHP-C was not used at our hospital. This project was approved by the Institutional Review Board of the University of Texas Southwestern Medical Center and Parkland Hospital.
The primary outcome of interest was recurrent preterm birth in women treated with 17 OHP-C. Every woman underwent a detailed review of her obstetric history by a research nurse using a prespecified manual of operations. Review included the number of previous births, gestational age at preterm birth, reason(s) for preterm delivery, and perinatal outcome. Women with a prior medically indicated preterm deliveryesuch as pregnancy hypertension or placental abruptionewere excluded. The study estimate of gestational age was based on the date of the last menstrual period and sonography. Data on obstetric history were linked to a preexisting computerized obstetric database. This database contains maternal and infant outcomes for all women delivered at Parkland Hospital.
17-alpha Hydroxyprogesterone caproate
A local pharmacy provided compounded single-dose vials of 250 mg of 17 OHP-C in sesame oil prepared in batches and delivered to the Parkland Hospital Pharmacy. Each batch was assayed for both potency and purity by an independent laboratory testing service (Eagle Analytical Services, Houston, TX). Potency testing was performed to ensure that each dose contained not <90% and not >110% of the specified 250 mg/mL 17 OHP-C. Sterility testing was performed for bacteria, mold, yeast, and fungi. Our approach was similar to that reported by Chang and colleagues 18 who evaluated the quality of 17 OHP-C supplied by 15 compounding pharmacies and did not identify safety concerns when assessed as we have described. Each 250-mg dose was purchased retail at $24.99 including testing procedures. Injections were commenced between 16 0/7 and 20 6/7 weeks. Women received weekly injections at the Preterm Birth Clinic until 36 weeks, or delivery. This was the 17 OHP-C regimen reported by Meis et al 3 and which is in use throughout the United States.
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Assessment of clinical effectiveness
The primary outcome was the overall rate of recurrent preterm birth 35 weeks. This gestational age was chosen because it was the preexisting criteria for referral of women to the Preterm Birth Clinic. There were 3 secondary questions. First, did 17 OHP-C modify a woman's history of preterm birth when taking into account her number and sequence of preterm and term births? Second, was recurrence of preterm birth related to 17 OHP-C plasma concentration? Third, was duration of pregnancy modified by 17 OHP-C treatment compared to a prior preterm birth?
Number and sequence of prior preterm births An individual woman's risk for recurrent preterm birth is influenced by her past number of preterm birth(s) as well as the sequence of preterm and term births. 19 That is, the rate of recurrence depends on the number of prior preterm births as well as the sequence of both preterm and term infants. For example, a risk of recurrent preterm birth for a gravida 3 para 2 woman with a prior preterm birth followed by a term birth differs from a woman with a prior term birth followed by preterm birth. Our purpose was to measure the effectiveness of 17 OHP-C in women with such differing preterm and term pregnancy histories.
Relationship of 17 OHP-C plasma concentration to recurrent preterm birth Measurement of 17 OHP-C concentrations in plasma became available during the trial. We opted to measure 17 OHP-C concentrations to further validate use of our compounded progestogen. Specifically, we wanted to ensure that 17 OHP-C was present in the plasma and concentrations were similar to those reported in the literature. 20 Moreover, we wanted to examine the relationship between 17 OHP-C concentration and ajog.org OBSTETRICS Original Research spontaneous preterm birth. Blood was drawn coinciding with routine prenatal care blood draws at 24 and 32 weeks prior to administration of a scheduled 17 OHP-C injection. The 24-week blood draw was for universal screening for gestational diabetes. Quantitative measurement of plasma concentration of 17 OHP-C was performed using batch-run analyses and high-performance liquid chromatography-mass spectrometry with atmospheric pressure chemical ionization. All of these analyses were conducted by one of the coinvestigators (J.M.). We then analyzed the relationship of 17 OHP-C plasma concentrations to the rate of recurrent birth 35 weeks.
Severity of recurrent preterm birth
We sought to compare a specific woman's weeks of gestation at a prior preterm birth not treated with 17 OHP-C to the weeks of gestation achieved in women who were treated. 21 Put another way, we sought to determine the effects of 17 OHP-C on the length of pregnancy. To do this, we compared the change in duration of pregnancy in women with recurrent preterm birth after treatment with 17 OHP-C to women untreated and previously delivered preterm at our hospital. 22 
Screening for gestational diabetes
Universal screening for gestational diabetes has been in use at Parkland Hospital since 1998. A screening 50-g oral glucose challenge was performed at 24 weeks in nonfasting women. Women with screening serum values !140 mg/dL were tested with a 3-hour 100-g glucose tolerance test. Gestational diabetes was diagnosed when !2 of the following values were abnormal: fasting !105 mg/dL; 1-hour !190 mg/dL; 2-hour !165 mg/dL; and 3-hour !145 mg/dL. Women with gestational diabetes were managed in coordination with a specific Gestational Diabetes Clinic held at Parkland Hospital.
Sample size calculation and statistics
The historical rate of recurrent birth 35 weeks in the Parkland Hospital general obstetric population was 16.8% when 17 OHP-C was not in use. 22 This rate was used to calculate the sample size necessary to assess the effectiveness of 17 OHP-C. A sample size of 413 women was estimated for a 90% power to detect a one-third reduction in recurrent preterm birth (from 16.8-11.2%) using a 1-sided, 1-sample binomial test of size 0.025 (alpha ¼ 0.025), which is equivalent to a 2-sided test of 0.05. A 1-sided test was chosen because the anticipated change was a lowering of the recurrent preterm birth rate. Recurrence rates according to the number and sequence of specific histories of preterm and term pregnancies were also based on the Parkland Hospital general obstetric population prior to 17 OHP-C implementation. Demographic comparisons of 17 OHP-C treated women were done using a 3:1 case control population from the 5787 women with recurrent preterm births in the Parkland obstetric population between January 1 1988 and December 31 2011. Plasma concentrations of 17 OHP-C in women with recurrent preterm birth were compared to concentrations in women without recurrence using the Wilcoxon rank sum test. To assess severity of recurrent preterm birth, the change in gestational weeks of recurrent preterm births was compared using Student t test before and after 17 OHP-C treatment.
The composition of the 17 OHP-C study group was compared to the demographic characteristics of women in the historical cohort. To do this, it was necessary to match the prior preterm birth profiles of the women treated with 17 OHP-C to the historical cohort delivered after universal screening for gestational diabetes was instituted in 1998. A 3:1 matched control group design was used to match for prior preterm birth profile as well as maternal race and body mass index (BMI). Statistical analysis was performed using software (SAS 9.3; SAS Institute Inc, Cary, NC).
Results
From Jan. 1, 2012, through March 31, 2016, 456 consecutive women with prior births 35 weeks and encountered between 16 and 20 weeks were treated with 17 OHP-C and delivered either at Parkland Hospital (86%) or at community hospitals (14%) (Figure 1) . A total of 26 (6%) women were excluded from this analysis; 21 were lost to follow-up and 5 delivered <20 weeks' gestation. Selected demographic characteristics of the 430 remaining women treated with 17 OHP-C are shown in Original Research OBSTETRICS ajog.org 17 OHP-C treated women using maternal race, BMI, and specific history of prior preterm birth. Treatment with 17 OHP-C did not reduce the rate of recurrent preterm birth after controlling for these maternal demographic factors (recurrence rate 25% vs. 23%, 17 OHP-C treated vs. case control, respectively, P ¼ . As shown in Table 2 , the overall rate of recurrent preterm birth was 25% (N ¼ 106) for the entire cohort treated with 17 OHP-C compared to the 16.8% expected rate in the historical Parkland Hospital obstetric population (P ¼ 1.0, 1-sided test). All of the infants delivered of women treated with 17 OHP-C were liveborn. We next analyzed each pregnancy according to specific obstetric history. As shown in Table 2 , regardless of prior preterm birth number or sequence, 17 OHP-C did not significantly reduce the rates of recurrence.
Drug concentrations were available for 116 of the 17 OHP-C treated women at 24 weeks gestation and 101 at 32 weeks. The plasma concentration of 17 OHP-C was 10.2 AE 5.2 ng/mL and 12 AE 5.9 ng/mL at 24 weeks and 32 weeks, respectively. When analyzed at either blood draw time point, concentrations of 17 OHP-C were not different (P ¼ .17 at 24 weeks; P ¼ .38 at 32 weeks) between women delivered 35 weeks and those delivered later in pregnancy (Figure 2) . Moreover, the plasma concentrations of 17 OHP-C corresponded to the concentrations reported by Caritis and colleagues. 20 The change in gestational weeks of recurrent preterm births in women treated with 17 OHP-C was compared to the change in weeks gestation in women previously untreated with 17 OHP-C but who delivered a recurrent preterm infant (Figure 3) . The mean (AESD) interval in weeks of recurrent preterm birth before 17 OHP-C use was 0.4 AE 5.3 weeks and the interval of recurrent preterm birth after 17 OHP-C was 0.1 AE 4.7 weeks. There was not a statistical difference (ie, improvement) in the interval weeks of recurrent preterm birth after the implementation of 17 OHP-C in our practice (P ¼ .63).
A total of 56 (13.4%) women treated with 17 OHP-C were diagnosed with gestational diabetes (all but 13 women given 17 OHP-C had complete evaluations for gestational diabetes). Using 3:1 matched (control:case) for prior preterm birth profile, maternal race, BMI, and universal screening for gestational diabetes, a total of 104 (8%) of the matched women not given 17 OHP-C were diagnosed with gestational diabetes (P ¼.001).
Comment
We introduced a new intervention to our obstetric service and felt a need to measure the effectiveness of 17 OHP-C when given to prevent recurrent preterm birth. When prospectively compared to a historical cohort at our hospital, 17 OHP-C did not improve the overall rate of recurrent preterm birth. We examined 3 secondary outcomes. First, the rates of recurrence were not improved by 17 OHP-C when analyzed according to the specific sequence of prior preterm and term births. Second, 17 OHP-C plasma concentrations were not different in women with and without recurrence. Third, 17 OHP-C did not significantly increase the duration of pregnancy when those women with a recurrent preterm birth were compared to similar women not previously treated with 17 OHP-C. A side effect of 17 OHP-C treatment was a significantly increased rate of gestational diabetes compared to case-matched historical controls, 13.4% vs 8%, for 17 OHP-C treated vs untreated, respectively. ajog.org
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Background
The study of 17 OHP-C to prevent preterm birth is not new. In 1975, Johnson and colleagues 23 randomized 43 women with prior preterm births or spontaneous abortions to weekly 250-mg injections of 17 OHP-C or placebo to test the efficacy of a progestogen in preventing premature labor. Prior to this study, progestogens were used primarily in the prevention of spontaneous abortion rather than prevention of preterm birth. These investigators found that 41% (9/22) of women given placebo delivered preterm compared to 0 (of 14 women) given 17 OHP-C (P < .02). 23 In contrast, Hauth and colleagues 24 (1983) studied the efficacy of 17 OHP-C in a heterogeneous group of women on active military duty and found no beneficial effect. A total of 168 women were randomized: 80 women were allocated to 17 OHP-C 1000 mg intramuscular weekly and 88 were allocated to placebo. Premature labor occurred in 5/80 (6%) women given 17 OHP-C compared to 5/88 (6%) randomized to placebo (P ¼ .88). Keirse 25 analyzed 7 trials of 17 OHP-C published from 1964 through 1985 using meta-analysis and found that 17 OHP-C was associated with a reduction in preterm birth from 28-16% (odds ratio, 0.5; 95% confidence interval, 0.3e0.85). This meta-analysis was influential in the choice of 17 OHP-C for the Meis et al trial 3 that ultimately rekindled interest in the use of progestogens to prevent preterm birth. 25 Meis et al 3 reported a reduction in recurrence in 463 women randomized (2:1) to receive 17 OHP-C or placebo with delivery <37 weeks in 111/306 (36%) women receiving 17 OHP-C compared to 84/153 (55%) receiving placebo (P < .001). As a result of this study, 17 OHP-C has become established in obstetric practice in the United States for prevention of recurrent preterm birth. [11] [12] [13] Some have voiced concerns [26] [27] [28] [29] about the Meis et al 3 trial. For example, in the FDA review of the Meis et al 3 trial, there was concern for the unexpectedly high rate (55%) of recurrent preterm birth in the control population. The expected rate had been 37%. The problem was that the preterm birth rate was 36% in the 17 OHP-C group, which was significant only in comparison to the unexpected 55% control group rate. One conclusion was that the benefit attributed to 17 OHP-C was only seen because the rate of recurrence in the control group exceeded the expected frequency.
An explanation offered for such a high rate of preterm birth in the control group was asymmetry in risk of recurrence. That is, the more prior preterm births a woman has, the greater the recurrence risk. Indeed, 41% of the control women in the Meis et al 3 trial had !2 prior preterm births compared to 28% in the 17 OHP-C group (P ¼ .004). Correspondence and commentary to the publication of the Meis et al 3 report raised another possibility for the higher rate of preterm birth in the control group. 29, 30 Brancazio and coauthors 30 suggested the possibility that the castor oil placebo used by Meis et al 3 could be implicated in stimulation of preterm uterine activity. Specifically, Brancazio and co-authors 30 observed that castor oil was previously used to induce labor. Meis et al 3 responded that this explanation was unlikely because castor oil was used as the vehicle in the 17 OHP-C group as well the control group. 30 Moreover, Meis et al 3 contend that castor oil in the small doses used in their trial was not recognized as an effective agent for inducing labor in pregnant women. 30 Recent laboratory evidence suggests otherwise with O'Sullivan and colleagues 31 reporting that human myometrial strips exposed to castor oil resulted in enhanced oxytocininduced contractility. Because of these concerns related to castor oil, we chose to use sesame oil as the vehicle for 17 OHP-C in our study. We point out that 17 OHP-C plasma concentrations using sesame oil as the vehicle were virtually identical to prior reported levels using castor oil. 20 Romero and Stanczyk 27 had another concern about the Meis et al 3 trial. The Meis et al 3 trial was completed in 2 phases. The first phase included 150 subjects when it had to be stopped because of reported problems with the manufacture of 17 OHP-C. 26 The firstphase cases were not included in the final published report. 27 The rate of recurrence in the control group during the first phase was 36% compared to the 55% in the control group rate published by Meis et al. 3 Thus, this 36% rate was equivalent to the 17 OHP-C treated groups' expected 37% rateemeaning that 17 OHP-C was ineffective in the unpublished first phase of the Meis et al 3 trial.
Diabetogenic effects of progestogens
It has long been known that maternal hormones to include estrogen and progesterone increase and promote pancreatic beta-cell hyperplasia and increased insulin. 32 As pregnancy progresses, increased levels of a variety of hormones to include cortisol, prolactin, estrogen, and progesterone lead to insulin resistance, which is considered central to the glucose intolerance associated with gestational diabetes. In contrast to estradiol, which is considered a very weak diabetogenic factor, progesterone is considered a strong factor with peak elevation at about 32 weeks' gestation. Indeed, Rebarber and colleagues 33 studied the diagnosis of gestational diabetes in 557 women given weekly 17 OHP-C injections to prevent recurrent preterm birth compared to diagnosis of gestational diabetes in 1524 women with prior preterm births but not given 17 OHP-C. The incidence of gestational diabetes in the 17 OHP-C treated group was 12.9% compared to 4.9% in control subjects (P < .001). 33 These results are very much like our experience.
Basic science observations on 17 OHP-C for prevention of preterm birth
The biologic mechanisms by which progestogens prevent preterm birth are unknown. One proposed mechanism was that progestogens maintain uterine quiescence; however, the current hypothesis is that progestogens act as antiinflammatory agents, possibly at the level of the uterine cervix. [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] Nold and colleagues, 44 using a murine model, found that 17 OHP-C had no effect on the pathways involved in uterine contractility, uterine quiescence, or cervical remodeling. Elovitz and Mrinalini 45 also used a mouse model of localized uterine inflammation and found that pretreatment with 17 OHP-C before intrauterine endotoxin exposure significantly decreased the preterm birth rate. However, such use of 17 OHP-C was associated with significant maternal morbidity including behavioral changes and death. 45 In contrast, Furcron and colleagues 43 found that 17 OHP-C did not have local antiinflammatory effects at the maternal-fetal interface or the cervix, and that 17 OHP-C did not protect against endotoxin-induced preterm birth. Indeed, Furcron and colleagues 43 reviewed the basic science on progestogen effects and concluded that the laboratory evidence for 17 OHP-C to influence preterm birth were weak compared to vaginal progesterone.
Manuck and colleagues 46,47 studied the pharmacogenomics of 17 OHP-C in the prevention of preterm birth. This approach to evaluating the effects of 17 OHP-C was based on a human biologic fluid repository 46 collected during the trial by Meis et al. 3 Saliva was tested for 20 different progesterone receptor polymorphisms in 380 women. They found that an individuals' response to 17 OHP-C was modified by their progesterone receptor genotype. For example, 17 OHP-C treatment reduced preterm births in some women with DNA variants compared to increased preterm births in women with other DNA variants. Manuck and colleagues 47 also studied DNA extracted from stored blood buffy coats in 50 women managed at Intermountain Medical Center in Salt Lake City. Women who benefitted (ie, responded) to 17 OHP-C had specific overrepresented genes. Taken together, these investigations by Manuck and colleagues 46, 47 suggest that the benefits of 17 OHP-C in prevention of recurrent 
OHP-C pricing concerns
Other concerns about 17 OHP-C for prevention of recurrent preterm birth involve the FDA approval history and subsequent price-gouging claims. 14, 48 In 2006, a New Drug Approval application was submitted to the FDA for 17 OHP-C. The initial application was denied and the FDA called for a confirmatory randomized trial with a larger sample size than the Meis et al 3 trial. 27 The rights to manufacture 17 OHP-C were subsequently bought by KV Pharmaceutical. Once a confirmatory study was underway and 10% of the total sample size had been recruited from US sites, the FDA gave temporary approval to KV Pharmaceutical on Feb. 11, 2011, to market 17 OHP-C under the brand name Makena. 48 This approval was granted under the agency's accelerated approval regulations. On Feb. 15, 2011, KV Pharmaceutical announced the price of Makena to be $1500 per injection. Given that pharmaceutical regulations prohibit compounding pharmacies from producing products that are commercially manufactured, KV Pharmaceutical had no competitors in pricing and was free to set the price as high as they thought the market would bear. 48 There was widespread concern over pricing because the drug cost of Makena would be >$30,000 per pregnancy. This was 75-150 times more than what formerly was being charged for the same medication that previously was available only through compounding pharmacies. 48 To put this pricing into context, if there are 133,000 women with prior preterm births delivered each year in the United States, 49 and each woman is given a total of 20 injections of 17 OHP-C (16-36 weeks), the income to the manufacturer using half-price, ie, $750 per 250-mg dose of 17 OHP-C, totals $1,990,000,000 per year. This almost $2 billion can be compared to the $25 per 250-mg dose (including potency and purity testing) for the 17 OHP-C used in our study that would total $66.5 million to treat these 133,000 women. This highlights the impact of a 30-fold increase in drug cost.
Generally, the FDA exercised enforcement discretion for most products made through traditional pharmacy compounding thus prohibiting producing compounded products that are commercially available. However, the FDA decided in the case of 17 OHP-C to not take enforcement action against pharmacies that compound this drug and compounded 17 OHP-C has consequently been available within the United States.
Are the results of randomized trials always validated in subsequent practice? 51 Two trials are usually required because of the importance of reproducibility. 52 The importance of reproducibility can be traced to Bradford-Hill, 52 who developed 9 criteria for how to separate causation from simple association. Fifty years after Bradford-Hill, 52 Ioannidis 53 assessed how well each of the 9 criteria functioned and found reproducibility paramount in strengthening a cause-and-effect conclusion. Reproducibility was deemed to strengthen the cause-and-effect relationship if there were consistent findings observed by different persons in different places with different studies. 53 When well-conducted, randomized controlled trials have internal validity, meaning the ability to attribute cause and effect to the tested intervention which in our study was 17 OHP-C. Internal validity here means a carefully circumscribed experimental population that share likeliness to meet specified randomized controlled trial inclusion criteria. However, this can be a limitation when results of randomized controlled trials are applied to a more heterogeneous population deemed "real-world." The criticism here is that the results of randomized controlled trials may not be generalizable to realworld populations. 17, 54 An example of this failure of generalizability is the recently reported trial titled, "A population-based, multifaceted strategy to implement antenatal corticosteroid treatment vs standard care for the reduction of neonatal mortality due to preterm birth in low-income and middle-income countries: the ACT cluster-randomized trial" (ACT trial), where antenatal corticosteroid treatment was randomized in a study aimed at reducing neonatal mortality due to preterm birth in 349 total health facilities located in Argentina, Guatemala, India, Kenya, Pakistan, and Zambia. 55 Clearly, use of antenatal corticosteroids based on a systematic review of 21 randomized controlled trials has become a touchstone in contemporary perinatal therapy. 56 Indeed, the systematic review showed a 31% relative reduction in neonatal mortality when antenatal corticosteroids were used in populations studied in the industrialized world. 56 It was anticipated by the investigators of the ACT trial that administering antenatal corticosteroids to women at high risk for preterm birth in populations where access to modern contemporary perinatal care was limited could dramatically reduce neonatal deaths. 55 That is, antenatal corticosteroids administration offered the possibility of an inexpensive lowtechnology means of reducing neonatal mortality. 55 The ACT trial took place from 2011 through March 2014 and included 48,219 women in the antenatal steroid group compared to 51,523 women in the control group. 55 Among the whole population, 28-day neonatal mortality was 27.4 per 1000 livebirths for the intervention group and 23.9 per 1000 livebirths for the control group (relative risk, 1.12; 95% confidence interval, 1.02e1.22; P ¼ .0127). 55 Instead of the expected
Original Research OBSTETRICS ajog.org reduction in neonatal mortality, there was an excess of 3.5 neonatal deaths for every 1000 women given antenatal steroids. 55 This result was attributed to the lack of access to ultrasound and neonatal intensive care in the populations studied. 57 A recent study of ultrasound in similar countries (Pakistan, Kenya, Zambia, and Guatemala) suggests that ACT failed due to lack of ultrasound. 58 Nonetheless, results of multiple randomized controlled trials were clearly not generalizable.
The lack of generalizability, which refers to external validity, becomes important when new therapies are applied in real-world settings. Nallamothu and coauthors 54 writing in a report titled, "Beyond the randomized clinical trial," distinguished between efficacy (treatment that works under ideal circumstances as in a randomized controlled trial) and effectiveness (treatment that works in realworld circumstances). These authors concluded that observational studies are essential follow-on studies for translating findings from randomized controlled trials into routine clinical practice. 54 Most recently, Sherman and colleagues, 17 writing on real-world evidence, observed that there is increased interest in exploring and integrating clinical research into more diverse real-world settings by capitalizing on the exponential growth in access to data from electronic health records and other existing data sets. They mention studies involving historical controls such as used in our study. 17 In the case of 17 OHP-C, the evidence date includes only 1 randomized controlled trial with a FDA-required second trial in progress. We note that postmarket clinical research on drugs is generally considered phase IV and that observational trials are included as a legitimate method for phase IV studies.
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Conclusions
We wish to emphasize that our study of the effectiveness of 17 OHP-C was unusual in that we not only assessed the overall effect of 17 OHP-C on recurrence of preterm birth but also the effect on preterm birth recurrence in the context of variations in recurrence patterns.
Specifically, the risk of recurrence intensifies in proportion to the number of prior preterm births as well as the order of term/preterm, preterm/term births in the obstetric history. We summarize our experiences with the conclusion that we were unable to demonstrate any benefit for 17 OHP-C to prevent recurrent preterm birth. We did find a side effect, specifically increased gestational diabetes, when 17 OHP-C was used. We conclude that the failure of 17 OHP-C for prevention of recurrent preterm birth at our hospital and the published evidence on effectiveness suggests that 17 OHP-C for prevention of recurrent preterm birth taken as a whole is at best problematic and has an important side effect.
n
